SAN

82.48

+0.01%↑

MRK1

112.3

+0.36%↑

SHL.DE

46.8

-0.28%↓

ARGX

478.8

+0.23%↑

FRE

42.51

+0.83%↑

SAN

82.48

+0.01%↑

MRK1

112.3

+0.36%↑

SHL.DE

46.8

-0.28%↓

ARGX

478.8

+0.23%↑

FRE

42.51

+0.83%↑

SAN

82.48

+0.01%↑

MRK1

112.3

+0.36%↑

SHL.DE

46.8

-0.28%↓

ARGX

478.8

+0.23%↑

FRE

42.51

+0.83%↑

SAN

82.48

+0.01%↑

MRK1

112.3

+0.36%↑

SHL.DE

46.8

-0.28%↓

ARGX

478.8

+0.23%↑

FRE

42.51

+0.83%↑

SAN

82.48

+0.01%↑

MRK1

112.3

+0.36%↑

SHL.DE

46.8

-0.28%↓

ARGX

478.8

+0.23%↑

FRE

42.51

+0.83%↑

Search

Laboratorios Farmaceuticos Rovi SA

Cerrado

SectorSalud

54.75 1.01

Resumen

Variación precio

24h

Actual

Mínimo

53.9

Máximo

54.95

Métricas clave

By Trading Economics

Ingresos

-57M

32M

Ventas

199M

434M

P/B

Media del Sector

19.78

50.291

BPA

0.354

Rentabilidad por dividendo

1.73

Margen de beneficio

7.411

Empleados

2,197

EBITDA

40M

138M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+65.9% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

1.73%

2.40%

Próximas Ganancias

30 jul 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-589M

2.8B

Apertura anterior

53.74

Cierre anterior

54.75

Puntuación técnica

By Trading Central

Confianza

Weak Bullish Evidence

Laboratorios Farmaceuticos Rovi SA Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

27 jun 2025, 20:51 UTC

Ganancias

These Stocks Moved the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27 jun 2025, 20:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

27 jun 2025, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

27 jun 2025, 20:48 UTC

Charlas de Mercado

Computer Lobby Cheers Move to Punish Canada Over Digital Tax -- Market Talk

27 jun 2025, 20:46 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

27 jun 2025, 20:46 UTC

Charlas de Mercado

Canada Dismissal of Risk From Digital Tax Is 'Shocking' -- Market Talk

27 jun 2025, 19:31 UTC

Charlas de Mercado

Canada CEOs Call for Carney to Drop Digital Tax -- Market Talk

27 jun 2025, 19:19 UTC

Charlas de Mercado

Oil Posts Weekly Loss As Geopolitical Premium Evaporates -- Market Talk

27 jun 2025, 19:16 UTC

Charlas de Mercado

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

27 jun 2025, 18:57 UTC

Adquisiciones, fusiones, absorciones

Russian Oligarch Roman Abramovich Is Evraz PLC's Largest Shareholder With 29% Stake -- WSJ

27 jun 2025, 18:57 UTC

Adquisiciones, fusiones, absorciones

Evraz North America Parent Evraz PLC Remains Under Sanction by U.K. -- WSJ

27 jun 2025, 18:57 UTC

Adquisiciones, fusiones, absorciones

Evraz North America Employs About 3,400 People, Has 3.5 Million Tons of Finished Steel Capacity -- WSJ

27 jun 2025, 18:57 UTC

Adquisiciones, fusiones, absorciones

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27 jun 2025, 18:57 UTC

Adquisiciones, fusiones, absorciones

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27 jun 2025, 18:42 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

27 jun 2025, 18:42 UTC

Charlas de Mercado

Canada's Carney 'Likely Amenable' to Dropping Digital-Services Tax -- Market Talk

27 jun 2025, 18:39 UTC

Charlas de Mercado
Ganancias

Nike's Second-Half Prospects Can Get Better as Worst is Behind it -- Market Talk

27 jun 2025, 18:29 UTC

Charlas de Mercado

Canada Recession Risks Likely to Rise With Trump's Termination of Tariff Talks -- Market Talk

27 jun 2025, 18:18 UTC

Charlas de Mercado

Canadian Dollar Sharply Weakens on Trump's Surprise End to US-Canada Tariff Talks -- Market Talk

27 jun 2025, 18:16 UTC

Charlas de Mercado

Trump's Threat Against Canada Weighs Down Treasurys -- Market Talk

27 jun 2025, 17:16 UTC

Charlas de Mercado

U.S. Oil Rig Count Falls by 6 to 432 -- Market Talk

27 jun 2025, 17:08 UTC

Ganancias

McDonald's Stock Has Slipped. One Analyst Sees 21% Upside. -- Barrons.com

27 jun 2025, 16:52 UTC

Adquisiciones, fusiones, absorciones

Nike Stock Soars After Earnings. Is It Time to Just Buy It? -- Barrons.com

27 jun 2025, 16:22 UTC

Ganancias

These Stocks Are Moving the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27 jun 2025, 16:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

27 jun 2025, 16:20 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

27 jun 2025, 16:20 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

27 jun 2025, 16:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

27 jun 2025, 15:59 UTC

Charlas de Mercado

Gold Futures Slump on Improving Risk Appetite -- Market Talk

27 jun 2025, 15:56 UTC

Charlas de Mercado

Nvidia Again Helping To Power New S&P Highs -- Market Talk

Comparación entre iguales

Cambio de precio

Laboratorios Farmaceuticos Rovi SA Esperado

Precio Objetivo

By TipRanks

65.9% repunte

Estimación a 12 meses

Media 90 EUR  65.9%

Máximo 90 EUR

Mínimo 90 EUR

De acuerdo con 1 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Laboratorios Farmaceuticos Rovi SA Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

1 ratings

1

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

51.1 / N/ASoporte y Resistencia

Corto Plazo

Weak Bullish Evidence

Medio plazo

Strong Bullish Evidence

Largo Plazo

Weak Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.